<DOC>
	<DOCNO>NCT01827540</DOCNO>
	<brief_summary>To evaluate PK , safety tolerability Cenicriviroc ( CVC ) administer without Dolutegravir ( DTG ) CVC without single dose Midazolam healthy subject .</brief_summary>
	<brief_title>Study Dolutegravir ( DTG ) PK Cenicriviroc ( CVC ) , CVC PK DTG &amp; Single Dose Midazolam</brief_title>
	<detailed_description>Primary Objectives - To evaluate steady-state PK CVC administer without DTG . - To evaluate steady-state PK DTG administer without CVC . - To evaluate PK single dose Midazolam administer without steady state CVC administer orally . Secondary Objectives - To evaluate safety tolerability CVC administer without DTG . - To evaluate safety tolerability CVC administer without Midazolam .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Provide write informed voluntary consent 2 . Adult male female healthy volunteer 3 . Body mass index ( BMI ) ≥ 18.0 ≤ 30.0 kg/m2 . 4 . Be good general health clinically relevant abnormality 5 . Agree comply study procedure restriction 1 . Any disease condition might affect drug absorption , metabolism , excretion , clinically significant cardiovascular determine investigator 2 . History stomach intestinal surgery , except fully heal appendectomy and/or cholecystectomy allow 3 . Clinically significant illness clinically significant surgery within 4 week administration study medication 4 . Known suspected hypersensitivity allergic reaction component CVC DTG tablet , midazolam syrup 5 . Serum ALT , AST , bilirubin value great equal Division Acquired Immunodeficiency Syndrome ( DAIDS ) grade 1 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>Cenicriviroc ( CVC )</keyword>
	<keyword>Dolutegravir ( DTG )</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>